Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress
Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call on November 4, 2021, at 5:00 p.m. ET to discuss its corporate and financial results for Q3 2021. The call can be accessed via phone or online, with an archive available for 90 days post-event. Salarius is focused on developing treatments for cancers with high unmet medical needs, including their lead candidate, seclidemstat, currently in clinical trials for Ewing sarcoma and other cancers. The company has received multiple designations from the FDA, highlighting its commitment to advancing oncology treatments.
- Seclidemstat is in Phase 1/2 clinical trials for Ewing sarcoma with multiple FDA designations.
- Financial support from the National Pediatric Cancer Foundation and CPRIT to advance clinical programs.
- None.
Conference Call and Live Audio Webcast Scheduled for Thursday, November 4, 2021, 5:00 p.m. ET
HOUSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced that the Company will host a conference call and live audio webcast on Thursday, November 4, 2021, at 5:00 p.m. ET, to discuss its corporate and financial results for the three and nine months ended September 30, 2021.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (833) 423-0481 (U.S.)
- (918) 922-2375 (International)
- Conference ID: 1514667
An audio webcast will be accessible via the Investors Events and Presentations section of the Company’s website http://investors.salariuspharma.com/. An archive of the webcast will remain available for 90 days beginning at approximately 6:00 p.m. ET, on November 4, 2021.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study underway at MD Anderson Cancer Center in hematologic cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.
Contact
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA (investors)
(212) 375-2664
mmcenroe@tiberend.com
Johanna Bennett (media relations)
(212) 375-2686
jbennett@tiberend.com
FAQ
When is the Salarius Pharmaceuticals conference call scheduled?
What financial results will Salarius Pharmaceuticals discuss?
How can I access the Salarius Pharmaceuticals conference call?
What is Salarius Pharmaceuticals' lead candidate?
What designations has seclidemstat received from the FDA?
